Elysium Bio
항암제/항바이러스제
Elysium Bio
Anticancer/Antiviral
암치료와 바이러스 감염예방제 및 치료제의 획기적인 신약을 제공합니다.
We provide groundbreaking new drugs for cancer treatment and prevention and treatment of viral infections.
(주)엘리시움바이오는 가장 중요하게 여기고 가치를 두는
특별한 세 가지를 비즈니스 목표로 삼고 있습니다.
Elysium Bio Co., Ltd. has three special priorities that it values most highly as its business objectives.
항암제 임상실험 및 일부 출시
Clinical trials of anticancer drugs and some market launches
Big Pharma 조기 라이선스아웃 실시
Early licensing out to Big Pharma
신약 시제품 제작 및 판매
Prototyping and selling for new medicine
(주)엘리시움바이오는 첨단 세포치료 기술을 이용하여 다양한 난치성 질환의 치료제를 개발하고,
고품질의
신약 생산을 통하여 건강하고 아름다운 삶을 영위하는데 목표를 두고 있습니다.
Elysium Bio Co., Ltd. aims to develop treatments for various intractable diseases using advanced cell therapy technology and to produce high-quality new drugs for a healthy and beautiful life.
사명변경 후 기업등록, 기업부설연구소 설치
엘리시움 셀 바이오 이탈리아 연구 협약서 체결 및 바이러스 예방제 아시아 판권 획득
엘리시움 바이오 바이러스 예방제 아시아 판권 획득
연세대학교 약학대학 용역 계약 체결
이화여자대학 약학대학 기술이전 계약 체결
연세대학교 약학대학 산학협력단 입주 등록
AI블록체인 기술기업 A락과 MOU 체결
(주)엘리시움바이오는 다양한 난치성 질환 치료제 개발과
고품질의 신약 생산을 위해 각 분야의 전문가와
함께합니다.
Elysium Bio Co., Ltd. collaborates with experts in various fields for the development of treatments for various intractable diseases and the production of high-quality new drugs.
Hong Yeoul Kim, CEO
30 years research experience in the bio field
- Professor of Biochemistry, Kyunghee University
- Health and Medical Evaluation professional evaluation
- Committee, Health and Welfare Department Ph.D. program, University of Warwick, UK
Gyun Hee Han, Ph.D.
Professor of Biotechnology, Yonsei University / College of Pharmacy
- 1992-1997 Doctor of Chemistry, Graduate School of Pennsylvania State University
- 1988-1990 Master of Pharmacy, Graduate School of Seoul National University
- 1984-1988 Bachelor of Pharmacy, Seoul National University
Yoon-Seok Kam, Ph.D.
Professor of Life Sciences, KAIST
- KAIST, PhD, Life Sciences
- KAIST, M.Sc., Life Sciences
- KAIST, B.S., Biotechnology
- Evolutionary strategies for systemic treatment of metastatic breast cancer: balancing response and resistance suppression
Namgoong Wan, Ph.D.
Professor of College of Pharmacy, Yonsei University
- Ph.D., 2003-2006, Yonsei University, Department of Medicine
- M.S., 2001-2003, Yonsei University, Department of Medicine
- B.S., 1995-2001, Yonsei University, Department of Biology
- High-throughput screening-based drug discovery
Dr. Kim Guk-rae, Ph.D.
Professor of College of Pharmacy, Yonsei University
- August 2016: Yonsei University, Seoul, South Korea
- Combined M.S. and Ph.D. Program in Systems Biology
- Advisor: Hyunsoo Cho, Ph.
- February 2006: Chungbuk National University, Chungju, South Korea
- B.S., Biology
Massimo Zollo Ph.D
Principal Investigator (PI)
- Full Professor of Genetics at the Department of Biotechnology, Federico II University of Naples.
- “Principal Investigator” in charge of the Laboratory of Molecular Genetics Research and Diagnostics in the Human Field at the CEINGE ‘Franco Salvatore’ Center of Excellence (Center for Genetic Engineering and Advanced Biotechnology) of MIUR.
Han, Hoon MD-Ph.D
Medical Doctor
- Professor, Catholic University of America
- Research Professor, UCLA, USA
- Founded the Catholic Bone Marrow (Information) Bank
- President of the Korean Society of Biomaterials
- 1st Science and Technology Outstanding Paper Award (Ministry of Science and Technology)
- The 23rd Yoohan Medical Award (Seoul Medical Association)
- The 9th Dongshin.SmithKline Grand Prize (Korean Medical Association)
- The 2nd BRM Academic Award
- 2010.5.7.6th Korea Knowledge Management Award (Bio Industry, JoongAng Ilbo)
Chang, Myung-Joon
MD-Ph.D
President Emeritus of the Korean Society for Growth
- Graduated from Hallym Medical College / M.D. from Kyungpook National University
- Board Certified in Internal Medicine/Gastrointestinal Endoscopy/Board Certified in Geriatrics/Board Certified in Growth Medicine/American Society for Anti-Aging
- 1991.2 Residency at Gangnam Sacred Heart Hospital, Hallim University
- 1992.2 Internal Medicine resident, Gangnam Sacred Heart Hospital, Hallim University
- 2017.8 CEO of Kidac (now Kymedi) - a platform for doctors (currently 45,000 members)
- 2020.10 Representative Director of 2,000-pyeong Yongin Screening Center
- 2023.08 Chief of Internal Medicine, Tae Pyeong Seoul Hospital
Elysium BIO 해결책 & 사업 모델
Elysium BIO Solutions & Business Model
신약물과 해결책을 통해 엘리시움 바이오의
혁신적인 신개념 바이러스 치료제를 선보이겠습니다.
We will introduce Elysium Bio's innovative new concept antiviral treatments through new drugs and solutions.
for kidney cancer
난치성 바이러스(RNA-virus)감영 예방 및 치료제 연구 개발
Research and development of prevention and treatment agents for intractable viral (RNA-virus) infections
엘리시움바이오·에스투시(S2C), 신약개발 공동연구 협약
Elysium Bio and S2C sign a joint research agreement for new drug development
YTN 사이언스
YTN Science
엘리시움바이오의 최신 정보와
중요 소식을 전달드립니다.
We provide the latest information and important news about Elysium Bio.
엘리시움바이오는 구성원의 조화로운 협업과 파트너의 동반 성장 가치를 믿으며, 이를 바탕으로 우리만의 특별한 조직도와 협력 비전을 소개합니다.
Elysium Bio believes in the value of harmonious collaboration among members and the co-growth of partners, and based on this, we introduce our unique organizational structure and cooperation vision.
국제 인공지능 관련 업체 조직도
Organizational chart of international AI-related companies
Elysium BIO 얼라이언스(STO)와의 협력방안
Cooperation plan with Elysium BIO Alliance (STO)
이탈리아 협력 기술 개발자
Technology developers in Italian collaboration
